CRSP Stock Overview
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CRISPR Therapeutics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.50 |
| 52 Week High | US$91.10 |
| 52 Week Low | US$37.55 |
| Beta | 1.69 |
| 11 Month Change | -16.94% |
| 3 Month Change | -14.01% |
| 1 Year Change | -4.33% |
| 33 Year Change | -61.03% |
| 5 Year Change | 1.63% |
| Change since IPO | 237.12% |
Recent News & Updates
Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Recent updates
Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09Shareholder Returns
| CRSP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | 1.7% | 0.4% |
| 1Y | -4.3% | 14.8% | 25.3% |
Return vs Industry: CRSP underperformed the US Biotechs industry which returned 14.8% over the past year.
Return vs Market: CRSP underperformed the US Market which returned 25.3% over the past year.
Price Volatility
| CRSP volatility | |
|---|---|
| CRSP Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRSP's share price has been volatile over the past 3 months.
Volatility Over Time: CRSP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
CRISPR Therapeutics AG Fundamentals Summary
| CRSP fundamental statistics | |
|---|---|
| Market cap | US$4.43b |
| Earnings (TTM) | -US$265.80m |
| Revenue (TTM) | US$202.23m |
20.8x
P/S Ratio-15.8x
P/E RatioIs CRSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRSP income statement (TTM) | |
|---|---|
| Revenue | US$202.23m |
| Cost of Revenue | US$484.70m |
| Gross Profit | -US$282.47m |
| Other Expenses | -US$16.67m |
| Earnings | -US$265.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | -139.68% |
| Net Profit Margin | -131.44% |
| Debt/Equity Ratio | 0% |
How did CRSP perform over the long term?
See historical performance and comparison